PL376470A1 - Sposób leczenia zespołu X za pomocą podstawionychtetralin i indanów - Google Patents

Sposób leczenia zespołu X za pomocą podstawionychtetralin i indanów

Info

Publication number
PL376470A1
PL376470A1 PL03376470A PL37647003A PL376470A1 PL 376470 A1 PL376470 A1 PL 376470A1 PL 03376470 A PL03376470 A PL 03376470A PL 37647003 A PL37647003 A PL 37647003A PL 376470 A1 PL376470 A1 PL 376470A1
Authority
PL
Poland
Prior art keywords
indanes
treating syndrome
substituted tetralins
tetralins
substituted
Prior art date
Application number
PL03376470A
Other languages
English (en)
Inventor
Xiaoli Chen
Keith T. Demarest
Jung Lee
Jay M. Matthews
Philip Rybczynski
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of PL376470A1 publication Critical patent/PL376470A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/08—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL03376470A 2002-10-21 2003-10-17 Sposób leczenia zespołu X za pomocą podstawionychtetralin i indanów PL376470A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41992702P 2002-10-21 2002-10-21
US49575803P 2003-08-15 2003-08-15

Publications (1)

Publication Number Publication Date
PL376470A1 true PL376470A1 (pl) 2005-12-27

Family

ID=32179770

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03376470A PL376470A1 (pl) 2002-10-21 2003-10-17 Sposób leczenia zespołu X za pomocą podstawionychtetralin i indanów

Country Status (17)

Country Link
US (2) US20040171680A1 (pl)
EP (1) EP1556344A1 (pl)
JP (1) JP2006503915A (pl)
KR (1) KR20050067419A (pl)
AU (1) AU2003279981A1 (pl)
BR (1) BR0315566A (pl)
CA (1) CA2503405A1 (pl)
CO (1) CO5690541A2 (pl)
EA (1) EA200500517A1 (pl)
HR (1) HRP20050337A2 (pl)
MX (1) MXPA05004296A (pl)
NO (1) NO20052277L (pl)
NZ (1) NZ539432A (pl)
PL (1) PL376470A1 (pl)
RS (1) RS20050319A (pl)
TW (1) TW200412935A (pl)
WO (1) WO2004037777A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009553B1 (ru) * 2002-10-21 2008-02-28 Янссен Фармацевтика Н.В. Замещённые тетралины и инданы
DK1554240T3 (da) * 2002-10-21 2009-08-17 Janssen Pharmaceutica Nv Substituerede tetraliner og indaner og deres anvendelse
EP1667958A2 (en) 2003-10-01 2006-06-14 The Procter & Gamble Company Melanin concentrating hormone antagonists
AR048931A1 (es) * 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
US7550467B2 (en) * 2004-10-12 2009-06-23 Schering Corporation Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
US20060263450A1 (en) * 2005-05-17 2006-11-23 Julius Oben Method and composition for reducing body weight and improving control of body lipids
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
US20100098793A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Irvingia gabonensis to treat and prevent metabolic syndrome and reduce total cholesterol, ldl cholesterol, blood glucose, c-reactive protein, and leptin levels and increasing adiponectin levels
US20100098792A1 (en) * 2008-10-17 2010-04-22 Gateway Health Alliances, Inc. Methods and compositions using irvingia gabonensis to reduce weight, control obesity, effect adipogenesis, lower ppar-gamma, leptin, g3pdh and triglycerides levels and increase adiponectin levels
US20130203769A1 (en) * 2012-02-08 2013-08-08 University Of Cincinnati Targeting Metabolic Adaptive Responses to Chemotherapy
WO2016092547A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Alcoholic beverage substitutes
WO2016092546A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Binge behavior regulators

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632809B2 (en) * 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
JP2003523336A (ja) * 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
BR0114437A (pt) * 2000-10-05 2003-07-01 Bayer Ag Derivados de acido propiÈnico
AU2002222549A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
WO2002046146A1 (fr) * 2000-12-05 2002-06-13 Kyorin Pharmaceutical Co., Ltd. Derives d'acide carboxylique substitues
JP2004517100A (ja) * 2000-12-20 2004-06-10 グラクソ グループ リミテッド hPPARアルファアゴニストとしての置換オキサゾールおよびチアゾール
US6548538B2 (en) * 2001-05-22 2003-04-15 Bayer Aktiengesellschaft Propionic acid derivatives
AU2002319627A1 (en) * 2001-07-20 2003-03-03 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
UA82835C2 (en) * 2001-12-03 2008-05-26 Reddys Lab Ltd Dr ?-aryl-?-oxysubstituted propionuc acid derivatives and pharmaceutical composition based thereon
EA009553B1 (ru) * 2002-10-21 2008-02-28 Янссен Фармацевтика Н.В. Замещённые тетралины и инданы
DK1554240T3 (da) * 2002-10-21 2009-08-17 Janssen Pharmaceutica Nv Substituerede tetraliner og indaner og deres anvendelse

Also Published As

Publication number Publication date
WO2004037777A1 (en) 2004-05-06
HRP20050337A2 (en) 2005-12-31
EP1556344A1 (en) 2005-07-27
KR20050067419A (ko) 2005-07-01
NZ539432A (en) 2008-04-30
BR0315566A (pt) 2005-08-23
CA2503405A1 (en) 2004-05-06
AU2003279981A1 (en) 2004-05-13
RS20050319A (sr) 2007-09-21
MXPA05004296A (es) 2005-11-23
NO20052277D0 (no) 2005-05-10
NO20052277L (no) 2005-06-29
EA200500517A1 (ru) 2005-10-27
JP2006503915A (ja) 2006-02-02
CO5690541A2 (es) 2006-10-31
TW200412935A (en) 2004-08-01
US20040171680A1 (en) 2004-09-02
US20040162352A1 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
TWI348329B (en) Electroluminescent devices and their manufacture
EP1539941A4 (en) ADZYMES AND THEIR USES
TWI340606B (en) Polymer compound and polymer luminous element using the same
AU2003270341A8 (en) Modified asialo-interferons and uses thereof
AU2002327874A8 (en) Antenna with one or more holes
IL166377A0 (en) Vrgfr-2 and vgefr-3 inhibitory and anthranylamidpyrimidines
HU0301063D0 (en) Benzoic-acid isononylesters and applying them
EG25097A (en) Piprazinyl and diazapanyl benzamides and benzthioamides.
PL372970A1 (pl) Element mocujący i układ mocujący
AU2003290341A8 (en) Electroluminescent materials and devices
GB0228335D0 (en) Electroluminescent materials and devices
AU2003215257A8 (en) Modified defensins and their use
GB0226408D0 (en) Catalyst and process
AU2003291087A8 (en) Ionene oligomers and polymers
GB0200365D0 (en) Software installation and operation
IL165112A0 (en) Variant integrinpolypeptides and thereof
EG24842A (en) Substituted tetralins and indanes
AU2003231827A8 (en) Pseudo-tissues and uses thereof
GB0228268D0 (en) Catalyst and process
AU2003228355A8 (en) Adipocytes and uses thereof
AU2003302173A8 (en) Spirotetrathiocarbamates and spirooxothiocarbamates
HK1078847A (en) Treating syndrome x with substituted tetralins and indanes
GB2407324B (en) Electroluminescent materials and devices
AU2003286389A8 (en) Ace-inhibitors having antioxidant and nitricoxid-donor activity
GB2406573B (en) Electroluminescent materials and devices

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)